National Institutes of Health

SonoMotion Inc. is a medical device company focused on developing non-invasive solutions for kidney stone disease. Founded in 2012 and based in San Mateo, California, the company offers innovative products such as Break Wave, which safely fragments large kidney stones, and Stone Clear, which aids in clearing the resulting stone fragments within 15 minutes in an office setting, without the need for general anesthesia or X-ray radiation. SonoMotion is actively involved in advancing its technology, with a stone repositioning solution currently undergoing clinical trials and a second-generation stone-breaking technology in development. The company's mission is to provide effective and cost-efficient treatments for kidney stone patients.

Arkansas Children's Research Institute is a not-for-profit organization affiliated with Arkansas Children's, Inc., and is dedicated to advancing pediatric health through research. It operates in conjunction with Arkansas Children's Hospital, the only pediatric medical center in Arkansas and one of the largest in the nation, which spans 29 city blocks and features 370 beds. The hospital employs around 500 physicians and more than 4,400 staff members, focusing on innovative medical research, surgical procedures, and intensive treatments aimed at improving children's health and development. The institute's research efforts contribute to the hospital's reputation for medical breakthroughs and have garnered recognition, including being ranked on the FORTUNE 100 Best Companies to Work For list for three consecutive years.

Feinstein Institute For Medical Research is the research arm of Northwell Health, the largest health care provider and private employer in New York State. Home to 50 research labs, 3,000 clinical research studies and 5,000 researchers and staff, the Feinstein Institutes raises the standard of medical innovation through its five institutes of behavioral science, bioelectronic medicine, cancer, health innovations and outcomes, and molecular medicine. We make breakthroughs in genetics, oncology, brain research, mental health, autoimmunity, and are the global scientific leader in bioelectronic medicine – a new field of science that has the potential to revolutionize medicine.

University of Arkansas for Medical Sciences is an academic health center focusing on medical education, research, and clinical programs. It offers various medical services, including specialized care in areas such as women's health, cancer treatment, orthopedics, stroke care, and trauma.

Sparian Biosciences is an early-stage biopharmaceutical company dedicated to the discovery and development of innovative therapies for the central nervous system (CNS). The firm focuses on creating unique medicines that target the brain, utilizing cutting-edge scientific approaches and novel drug discovery techniques. In addition to its core mission, Sparian is also developing a new analgesic aimed at addressing both acute and chronic pain, further emphasizing its commitment to advancing treatments for CNS-related conditions.

Brixton Biosciences is a clinical-stage life sciences company focused on developing innovative therapies for chronic and acute pain management. The company aims to address significant unmet needs in this area, which has traditionally relied on systemic medications. Its flagship product, Neural Ice™, is a drug-free injectable treatment designed to induce reversible inhibition of nerves, offering a non-addictive, locally targeted solution. This therapy provides patients with extended pain relief lasting from thirty to sixty days following a single injection, representing a significant advancement over current pain management methods.

Teal Health is dedicated to improving women's health by providing at-home cervical cancer screenings. The company has developed an FDA-approved device that allows women to perform these essential screenings in the comfort and privacy of their own homes. By simplifying the process, Teal Health aims to encourage timely screenings, which are crucial for early detection and treatment, ultimately striving to eradicate cervical cancer in the United States. The initiative is supported by a group of committed investors who share the vision of transforming women's health experiences.

Arkansas Children's Research Institute is a not-for-profit organization affiliated with Arkansas Children's, Inc., and is dedicated to advancing pediatric health through research. It operates in conjunction with Arkansas Children's Hospital, the only pediatric medical center in Arkansas and one of the largest in the nation, which spans 29 city blocks and features 370 beds. The hospital employs around 500 physicians and more than 4,400 staff members, focusing on innovative medical research, surgical procedures, and intensive treatments aimed at improving children's health and development. The institute's research efforts contribute to the hospital's reputation for medical breakthroughs and have garnered recognition, including being ranked on the FORTUNE 100 Best Companies to Work For list for three consecutive years.

Allyx Therapeutics, founded in 2018 and based in Durham, Connecticut, is a clinical-stage biotechnology company focused on developing disease-modifying treatments for Alzheimer's Disease. The company’s primary product is an orally bioavailable small molecule that functions as a silent allosteric modulator of mGluR5. This innovative drug aims to reverse neurodegeneration and offers a potential approach to preserve cognitive function in patients with Alzheimer's. By targeting the underlying mechanisms of the disease, Allyx Therapeutics strives to provide effective therapeutic solutions for those affected by neurodegenerative disorders.

Rosalind Franklin University of Medicine and Science, established in 1912, is a North Chicago, Illinois-based institution dedicated to educating future health science leaders. It comprises five schools offering degrees such as Doctor of Medicine, Doctor of Podiatric Medicine, Nurse Anesthesia, Physical Therapy, and Physician's Assistant. The university fosters research and provides opportunities for students to engage in it, both on campus and through partnerships with nearby institutions. It aims to enrich students' lives professionally, mentally, and socially through various organizations and activities. Admission requirements vary by school but generally seek students with a strong scientific background and leadership skills. The university offers financial aid to eligible students who demonstrate need.

The Oklahoma Medical Research Foundation (OMRF) is a non-profit biomedical research institute dedicated to understanding and treating various devastating illnesses, including Alzheimer's, heart disease, lupus, multiple sclerosis, and cancer. It operates a research facility, providing services and access to resources that facilitate drug discoveries and improve patient care.

Resvita Bio is engaged in the development and manufacturing of engineered probiotics aimed at treating skin-related diseases, including chronic conditions and cancer. The company focuses on creating a versatile skin microbial platform utilizing synthetic biology and metabolic engineering. This innovative approach allows for the continuous delivery of therapies that alleviate inflammation, promote tissue regeneration, and eliminate harmful bacteria. By leveraging this technology, Resvita Bio aims to offer faster and more efficient treatment alternatives for individuals suffering from chronic skin diseases.

Cenna Biosciences focuses on the discovery and development of innovative drugs aimed at preventing and treating Alzheimer's disease. The company utilizes a proprietary technology that targets the underlying cause of the disease, specifically addressing the harmful accumulation of beta-amyloid (Aß) in the brains of affected individuals. Cenna has identified a novel target and is in the process of developing several lead peptide compounds as potential disease-modifying treatments for Alzheimer's.

Tiziana Life Sciences is a clinical-stage biotechnology company based in London, UK, focused on discovering and developing novel therapeutic molecules for oncology and immunology. The company's product pipeline includes Foralumab, a human anti-CD3 monoclonal antibody aimed at treating autoimmune and inflammatory diseases such as graft-versus-host disease and multiple sclerosis. Another key asset is Milciclib, an orally bioavailable small molecule that inhibits cyclin-dependent kinases and is currently undergoing phase II clinical trials for epithelial thymic carcinoma. Additionally, Tiziana is developing Anti IL-6r, a monoclonal antibody targeting interleukin-6 for severe COVID-19 cases, and StemPrintER, a multi-gene signature assay for estrogen-receptor positive breast cancer patients. Founded in 2013, Tiziana Life Sciences is dedicated to advancing innovative therapies for serious diseases, including neurodegenerative disorders and lung diseases.

TransCode Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Boston, Massachusetts, focused on the discovery and development of microRNA (miRNA) therapeutics to treat metastatic diseases. Founded in 2016, the company is dedicated to combating cancer through the targeted eradication of metastatic tumor cells, primarily leveraging its proprietary TTX nanoparticle platform. Its lead therapeutic candidate, TTX-MC138, aims to inhibit microRNA-10b, a key biomarker associated with metastasis, and has shown promising preclinical validation. Additionally, TransCode is advancing a portfolio of innovative RNA therapeutic candidates designed to address the challenges of RNA delivery, thereby expanding therapeutic options for various genetic targets within oncology.

Subtle Medical, Inc. is a healthcare technology company based in Menlo Park, California, that specializes in developing AI-powered medical imaging software for clinical imaging centers and hospitals. Founded in 2017, the company offers products such as SubtleMR and SubtlePET, both of which are FDA cleared and CE marked. These technologies enhance image quality in magnetic resonance imaging (MRI) and positron emission tomography (PET) exams by reducing noise and increasing sharpness, ultimately improving workflow efficiency while ensuring patient safety. Subtle Medical also features SubtleGAD, a technology recognized by the Radiological Society of North America, which aims to make imaging exams safer. The company employs a vendor-agnostic AI infrastructure that integrates seamlessly with existing scanners, allowing imaging providers to serve more patients effectively by enhancing image acquisition without disrupting their current workflow. Through its innovations, Subtle Medical seeks to improve the quality, value, and accessibility of medical imaging while significantly lowering costs and radiation exposure.

Precision Epigenomics, established in 2020 and based in Tucson, Arizona, specializes in molecular diagnostics for cancer. The company focuses on developing innovative molecular diagnostic assays, leveraging DNA methylation analysis, an epigenetic modification, to enhance cancer diagnosis and treatment. Their offerings aim to address unmet clinical needs, aiding clinicians in improved patient management.

Ensysce Biosciences is a clinical-stage biotechnology company focused on developing safer prescription drugs, particularly in the realm of opioid analgesics. Utilizing its proprietary technology platforms, specifically the Trypsin Activated Abuse Protection (TAAP) and Multi-Pill Abuse Resistance (MPAR), Ensysce aims to create tamper-proof opioids designed to mitigate the risks of addiction and accidental overdose. These innovative drug formulations are intended to provide effective pain relief while reducing the human and economic toll associated with opioid misuse. The company is backed by a comprehensive intellectual property portfolio covering diverse prescription drug compositions, positioning it to make a significant impact on the opioid crisis.

Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company based in Houston, Texas, that focuses on developing and commercializing T cell-based immunotherapies and peptide-based vaccines for hematological malignancies and solid tumors. The company’s MultiTAA technology enhances the effectiveness of non-engineered tumor-specific T cells, enabling them to target multiple tumor-associated antigens simultaneously. This approach aims to prevent immune escape and foster durable immunity. Marker Therapeutics offers autologous T cell therapies for conditions such as lymphoma and multiple myeloma, while also developing allogeneic T cell therapies for acute myeloid leukemia and acute lymphoblastic leukemia. Additionally, the company is advancing peptide-based vaccines, including TPIV100/110 and TPIV200, which are currently in Phase II clinical trials for treating breast and ovarian cancers, respectively.

Immunovia is a diagnostics company focused on the early detection of pancreatic cancer and other complex diseases. Utilizing its proprietary IMMray platform, which is based on antibody microarray analysis, Immunovia develops and commercializes innovative diagnostic tools. The company conducts clinical trials and validation studies to ensure the accuracy and reliability of its tests, collaborating with medical institutions and research centers worldwide. By concentrating on early detection, Immunovia aims to enhance the treatment and management of pancreatic cancer, thereby improving patient survival rates. The technology developed by Immunovia could also facilitate early detection strategies for other cancers and autoimmune diseases in the future.

University of Arkansas for Medical Sciences is an academic health center focusing on medical education, research, and clinical programs. It offers various medical services, including specialized care in areas such as women's health, cancer treatment, orthopedics, stroke care, and trauma.

Anebulo Pharmaceuticals is a clinical-stage biotechnology company focused on developing innovative treatments for individuals experiencing cannabinoid overdose and substance addiction. Its primary product candidate, ANEB-001, is designed to counteract the adverse effects of cannabinoid overdose within one hour of administration. Clinical trials have demonstrated that ANEB-001 is rapidly absorbed and well-tolerated by patients. Additionally, it has been observed to induce weight loss, an effect linked to its action as a central cannabinoid receptor type 1 antagonist. The company aims to address the wide range of symptoms associated with cannabinoid overdose, which can include profound sedation, anxiety, panic, and psychosis with hallucinations.

Arkansas Children's Research Institute is a not-for-profit organization affiliated with Arkansas Children's, Inc., and is dedicated to advancing pediatric health through research. It operates in conjunction with Arkansas Children's Hospital, the only pediatric medical center in Arkansas and one of the largest in the nation, which spans 29 city blocks and features 370 beds. The hospital employs around 500 physicians and more than 4,400 staff members, focusing on innovative medical research, surgical procedures, and intensive treatments aimed at improving children's health and development. The institute's research efforts contribute to the hospital's reputation for medical breakthroughs and have garnered recognition, including being ranked on the FORTUNE 100 Best Companies to Work For list for three consecutive years.

Weill Cornell Medicine operates as a leading medical and graduate school in New York City, focusing on excellence in patient care, scientific discovery, and the education of future physicians. The institution provides a comprehensive range of services, including medical consultancy, healthcare programs, and educational guidance, aimed at healthcare service providers, medical students, and governmental organizations. In addition to its educational mission, Weill Cornell Medicine includes specialized centers such as the Weill Cornell Vein Treatment Center, which offers treatments for various venous conditions and related health issues. The Information Technologies & Services Department plays a crucial role in supporting the institution’s objectives by delivering extensive IT infrastructure and services, enhancing research and clinical operations through innovative technology solutions. This multidisciplinary approach positions Weill Cornell Medicine as a leader in both medicine and technology.

Metabolon, Inc. is a health technology company specializing in metabolomics, focusing on the development of diagnostic tests and analytical methods for early disease detection and precision medicine. The company offers a range of clinical diagnostics, including QUANTOSE IR for measuring insulin resistance, QUANTOSE IGT for assessing glucose tolerance, and Meta IMD for identifying metabolites linked to inherited metabolic disorders. In addition to its diagnostic capabilities, Metabolon provides customizable research services and multiomics solutions to support academic and commercial investigations across various life science sectors. Its technologies are applicable in areas such as cardiovascular health, diabetes, oncology, and respiratory disorders. Founded in 2000 and headquartered in Morrisville, North Carolina, with additional offices in Europe and sales locations in the UK, Spain, and China, Metabolon collaborates with numerous strategic partners in the pharmaceutical and biotechnology industries to enhance research and development outcomes.

Ensysce Biosciences is a clinical-stage biotechnology company focused on developing safer prescription drugs, particularly in the realm of opioid analgesics. Utilizing its proprietary technology platforms, specifically the Trypsin Activated Abuse Protection (TAAP) and Multi-Pill Abuse Resistance (MPAR), Ensysce aims to create tamper-proof opioids designed to mitigate the risks of addiction and accidental overdose. These innovative drug formulations are intended to provide effective pain relief while reducing the human and economic toll associated with opioid misuse. The company is backed by a comprehensive intellectual property portfolio covering diverse prescription drug compositions, positioning it to make a significant impact on the opioid crisis.

Phenomix Sciences is a biotechnology company founded in 2017 and headquartered in New York, United States. It specializes in the fields of metabolomics and genomics, focusing on developing healthcare solutions for personalized management of chronic diseases. The company has created a data analysis platform aimed at precision medicinal research for obesity management, which features a novel blood test and an AI-driven algorithm. This platform classifies the unique pathophysiological phenotype of patients with obesity, providing healthcare centers with tools and services that enhance the efficacy of obesity management while also reducing side effects and overall costs.

Arkansas Children's Research Institute is a not-for-profit organization affiliated with Arkansas Children's, Inc., and is dedicated to advancing pediatric health through research. It operates in conjunction with Arkansas Children's Hospital, the only pediatric medical center in Arkansas and one of the largest in the nation, which spans 29 city blocks and features 370 beds. The hospital employs around 500 physicians and more than 4,400 staff members, focusing on innovative medical research, surgical procedures, and intensive treatments aimed at improving children's health and development. The institute's research efforts contribute to the hospital's reputation for medical breakthroughs and have garnered recognition, including being ranked on the FORTUNE 100 Best Companies to Work For list for three consecutive years.

University of Arkansas for Medical Sciences is an academic health center focusing on medical education, research, and clinical programs. It offers various medical services, including specialized care in areas such as women's health, cancer treatment, orthopedics, stroke care, and trauma.

Lamassu Pharma is a biotech startup dedicated to addressing the significant unmet medical need for severe acute pancreatitis. The company is focused on developing a novel small molecule therapy that has shown promising preclinical results in significantly reducing both mortality and morbidity associated with this condition. This therapeutic candidate, developed by leading scientists at Mayo Clinic, aims to improve medical outcomes for patients suffering from acute pancreatitis. Lamassu Pharma is currently advancing the development of this compound through safety testing, preparing for future clinical trials with the ultimate goal of saving lives and enhancing treatment options for those affected by this serious disease.

University of Arkansas for Medical Sciences is an academic health center focusing on medical education, research, and clinical programs. It offers various medical services, including specialized care in areas such as women's health, cancer treatment, orthopedics, stroke care, and trauma.

University of Arkansas for Medical Sciences is an academic health center focusing on medical education, research, and clinical programs. It offers various medical services, including specialized care in areas such as women's health, cancer treatment, orthopedics, stroke care, and trauma.

The Stark Neurosciences Research Institute is dedicated to improving outcomes for persons suffering from disorders of the nervous system.

Center for HIV Identification, Prevention, and Treatment Services is a research organisation that conducts HIV research. They offers customer support through email and phone contact.

L2P Research Labs is a preclinical contract research organization (CRO) that specializes in providing comprehensive research and development support. The company focuses on preclinical and toxicology services, utilizing proprietary orthotopic and metastatic tumor models. L2P Research Labs offers a range of advanced technologies, including quantitative whole-body animal imaging, small animal ultrasound, MRI, and CT scans, as well as focal radiation. These capabilities allow researchers to access a complete suite of research services tailored to their needs, facilitating the advancement of scientific studies and drug development.

Rational Vaccines is a preclinical stage company focused on developing innovative vaccines to combat herpes simplex virus and its related diseases. The company is dedicated to creating live-attenuated viral immunotherapeutic and prophylactic vaccine candidates that aim to reduce the transmission of the herpes virus and effectively manage symptoms associated with its reactivation. By harnessing rational engineering techniques, Rational Vaccines seeks to revolutionize the treatment, prevention, and diagnosis of herpes infections, ultimately improving the quality of life for those affected by these conditions.

Clene Nanomedicine, established in 2012 and headquartered in Salt Lake City, Utah, is a clinical-stage biopharmaceutical company dedicated to developing innovative therapeutics for neurodegenerative diseases. The company has pioneered a unique nanotechnology drug platform that enables the creation of orally-administered neurotherapeutic drugs. This technology, known as Clean-Surface Nanosuspension, produces clean-surface nanocrystal medicines and serves as a foundation for a pipeline of new drug candidates aimed at addressing various diseases with significant unmet medical needs. Clene Nanomedicine's primary focus areas include demyelinating disorders and oncology.

Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in New York, focused on developing radiotherapies for patients with cancer. The company's lead product candidate, Iomab-B, is undergoing a pivotal Phase III clinical trial as a conditioning agent for patients over the age of 55 with relapsed or refractory acute myeloid leukemia prior to bone marrow transplantation. Another key candidate, Actimab-A, is in Phase II trials targeting newly diagnosed acute myeloid leukemia in patients aged 60 and older. Additionally, Actinium is developing Actimab-M for penta-refractory multiple myeloma, currently in Phase I trials. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cancer cells, enhancing treatment efficacy while minimizing damage to healthy tissues. Actinium also collaborates with Astellas Pharma to advance its technology. Founded in 2000, Actinium Pharmaceuticals aims to address unmet medical needs in hematology through innovative therapeutic approaches.

Neurodon Corporation is focused on discovering and developing disease-modifying therapies for intractable diseases by addressing endoplasmic reticulum (ER) stress, a significant factor in cell dysfunction and death. The company's innovative approach utilizes first-in-class modulators to restore calcium levels in cells, enabling the creation of therapeutics for conditions such as Alzheimer's disease, Parkinson's disease, Huntington's disease, and diabetes. Founded in 2019 and based in Crown Point, Indiana, Neurodon has advanced two candidates into IND-enabling studies, with plans to commence clinical trials in 2025. The company has raised over $11 million through various funding sources, including grants and partnerships, and is currently seeking additional funding to support its upcoming clinical studies. Neurodon’s unique platform technology positions it as a leader in addressing diseases linked to ER stress, with no direct competitors targeting the same mechanism of action.

SpineX Inc. is a seed-stage medical device company focused on developing non-invasive neuromodulation devices aimed at addressing unmet medical needs in patients with neurological conditions. The company is engaged in clinical trials to evaluate the safety and effectiveness of its neuromodulation therapy specifically for individuals suffering from neurogenic bladder issues related to stroke, spinal cord injuries, or multiple sclerosis. SpineX's technologies are designed to enhance recovery and restore various functions, including bladder, bowel, respiration, sexual, and sensorimotor capabilities. One of its key products, the SCiP device, targets neurological dysfunction associated with conditions like cerebral palsy. By leveraging rigorously tested neuromodulation methods, SpineX aims to improve the quality of life for individuals affected by these debilitating conditions.

South Rampart Pharma is a clinical-stage life science company dedicated to developing safe and effective pain relief alternatives. The company focuses on synthesizing and characterizing new non-opioid and non-liver toxic molecules that target pain signaling pathways in the brain's periaqueductal grey (PAG) region. Its lead candidate, SRP-001, has received U.S. FDA Fast Track designation for acute pain treatment. This candidate aims to influence pain-related genes through various biological pathways, including endocannabinoid signaling and mechanical nociception, providing a promising solution to mitigate the risks associated with traditional pain medications, particularly their potential for abuse.

Glyphic Biotechnologies is a biotechnology company focused on developing an advanced protein sequencing platform that aims to enhance understanding of biological functions and diseases. Unlike DNA sequencing, which offers limited insights, this next-generation platform provides deeper knowledge through single-molecule, massively parallel sequencing. By improving binding affinity and consistency, Glyphic's technology supports the creation of personalized and precision cancer vaccines tailored to individual patients. The company's innovative approach enables scientists and researchers to develop novel therapeutics and diagnostics, ultimately advancing the comprehension of human biology and disease mechanisms.

Subtle Medical, Inc. is a healthcare technology company based in Menlo Park, California, that specializes in developing AI-powered medical imaging software for clinical imaging centers and hospitals. Founded in 2017, the company offers products such as SubtleMR and SubtlePET, both of which are FDA cleared and CE marked. These technologies enhance image quality in magnetic resonance imaging (MRI) and positron emission tomography (PET) exams by reducing noise and increasing sharpness, ultimately improving workflow efficiency while ensuring patient safety. Subtle Medical also features SubtleGAD, a technology recognized by the Radiological Society of North America, which aims to make imaging exams safer. The company employs a vendor-agnostic AI infrastructure that integrates seamlessly with existing scanners, allowing imaging providers to serve more patients effectively by enhancing image acquisition without disrupting their current workflow. Through its innovations, Subtle Medical seeks to improve the quality, value, and accessibility of medical imaging while significantly lowering costs and radiation exposure.

Glyphic Biotechnologies is a biotechnology company focused on developing an advanced protein sequencing platform that aims to enhance understanding of biological functions and diseases. Unlike DNA sequencing, which offers limited insights, this next-generation platform provides deeper knowledge through single-molecule, massively parallel sequencing. By improving binding affinity and consistency, Glyphic's technology supports the creation of personalized and precision cancer vaccines tailored to individual patients. The company's innovative approach enables scientists and researchers to develop novel therapeutics and diagnostics, ultimately advancing the comprehension of human biology and disease mechanisms.

The Buck Institute is the nation’s first independent research facility focused solely on understanding the connection between aging and chronic disease. Their mission is to increase the healthy years of life. At the Buck Institute, world-class scientists work in a uniquely collaborative environment to understand how normal aging contributes to the development of conditions specifically associated with getting older such as Alzheimer’s and Parkinson’s diseases, cancer, stroke, osteoporosis, heart disease, diabetes, macular degeneration and glaucoma. Their interdisciplinary approach brings scientists from disparate fields together to develop diagnostic tests and treatments to prevent or delay these maladies. The stakes have never been higher. While it’s true that people are living longer, those “extra” years are often marked by disability and pain. In addition to personal hardship, there is also a cost to society. The financial burden of treating the chronic diseases of aging is expected to rise steadily as Baby Boomers get older. There is an urgency to Their mission.

University of Oklahoma Health Sciences Center, as a comprehensive academic health center, is to educate students, residents, and other trainees in professional and graduate programs to become Oklahoma’s future team of healthcare leaders, clinicians, researchers, and educators; to advance distinctive basic, translational, clinical, and population research; to innovate and commercialize discoveries; and to deliver exceptional patient care across the full breadth of adult, women’s, and children’s specialties.

Morehouse School of Medicine, located in Atlanta, Georgia, is a historically Black college and university (HBCU) dedicated to training healthcare professionals, with a special emphasis on minority students. The institution offers a medical degree program along with master’s degrees in various fields, including Public Health and Biomedical Sciences. Medical students can specialize in areas such as Family Medicine, Internal Medicine, Obstetrics and Gynecology, Pediatrics, Psychiatry, and Surgery, completing clinical assignments at affiliated hospitals. The school is also engaged in research, focusing on cardiovascular studies, neuroscience, and health disparities. To support its mission, Morehouse manages an endowment fund, the earnings of which are utilized for scholarships, research funding, and academic programs. Admissions requirements vary by program, and the school provides scholarships aimed at supporting disadvantaged students, alongside academic and merit-based financial aid.

Inherent Biosciences is a molecular diagnostics company focused on transforming the trial and error approach in medicine by leveraging insights from epigenetics. The company aims to provide clarity on complex health issues by identifying dysregulation across multiple genes and pathways, which informs personalized treatment strategies. Inherent Biosciences develops innovative therapies for a range of conditions, including pain, infertility, embryo quality, autism, rheumatoid arthritis, psoriatic arthritis, fetal heart disease, and COVID-19. By translating biological discoveries into actionable insights, the company seeks to enhance patient care and improve outcomes in various medical fields.

Glyphic Biotechnologies is a biotechnology company focused on developing an advanced protein sequencing platform that aims to enhance understanding of biological functions and diseases. Unlike DNA sequencing, which offers limited insights, this next-generation platform provides deeper knowledge through single-molecule, massively parallel sequencing. By improving binding affinity and consistency, Glyphic's technology supports the creation of personalized and precision cancer vaccines tailored to individual patients. The company's innovative approach enables scientists and researchers to develop novel therapeutics and diagnostics, ultimately advancing the comprehension of human biology and disease mechanisms.

University of Arkansas for Medical Sciences is an academic health center focusing on medical education, research, and clinical programs. It offers various medical services, including specialized care in areas such as women's health, cancer treatment, orthopedics, stroke care, and trauma.

Kintara Therapeutics, Inc. is a clinical-stage drug development company focused on creating and commercializing innovative anti-cancer therapies for patients with unmet medical needs. The company is advancing two late-stage therapeutics: VAL-083, a DNA-targeting agent designed to treat drug-resistant solid tumors such as glioblastoma multiforme and ovarian cancer, and REM-001, a photodynamic therapy aimed at cutaneous metastatic breast cancer. Kintara has established a strategic collaboration with Guangxi Wuzhou Pharmaceutical (Group) Co. Ltd. for the manufacturing and sales of VAL-083 in China. Kintara Therapeutics was founded in 2009 and is headquartered in San Diego, California. The company seeks to address significant challenges faced by cancer patients who have not responded to conventional treatments.

The University of Texas MD Anderson Cancer Center is a leading institution dedicated exclusively to cancer patient care, research, education, and prevention. Located in the Texas Medical Center in Houston, Texas, it was established as one of the original three comprehensive cancer centers under the National Cancer Act of 1971. MD Anderson serves as both a degree-granting academic institution and a specialized cancer treatment facility. It is affiliated with two prominent medical schools: The University of Texas Medical School at Houston and Baylor College of Medicine. Renowned for its exceptional cancer care, MD Anderson has consistently ranked among the top cancer hospitals in the United States, earning the No. 1 position in U.S. News & World Report's "Best Hospitals" survey for ten of the past twelve years. The center is widely recognized for its commitment to advancing cancer treatment and improving patient outcomes.

Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company based in Houston, Texas, that focuses on developing and commercializing T cell-based immunotherapies and peptide-based vaccines for hematological malignancies and solid tumors. The company’s MultiTAA technology enhances the effectiveness of non-engineered tumor-specific T cells, enabling them to target multiple tumor-associated antigens simultaneously. This approach aims to prevent immune escape and foster durable immunity. Marker Therapeutics offers autologous T cell therapies for conditions such as lymphoma and multiple myeloma, while also developing allogeneic T cell therapies for acute myeloid leukemia and acute lymphoblastic leukemia. Additionally, the company is advancing peptide-based vaccines, including TPIV100/110 and TPIV200, which are currently in Phase II clinical trials for treating breast and ovarian cancers, respectively.

Shirley Ryan AbilityLab is a translational research hospital. Their services include spinal cord injury recovery, brain injury recovery, COVID recovery, pediatric and adolescent rehabilitation, nursing, cancer rehabilitation, limb loss and impairment, and pain management.

Aphios Corporation is a biotechnology company based in Woburn, Massachusetts, specializing in drug delivery and manufacturing technologies. Founded in 1993, Aphios develops innovative platforms that enhance drug discovery and ensure the safety of pharmaceuticals. The company focuses on creating therapeutic products aimed at health maintenance, disease prevention, and treatment of various conditions, including cancers, infectious diseases, and central nervous system disorders. Notable products include Zindol, a ginger-derived therapeutic, and several advanced formulations such as APH-0703, a protein kinase C activator, and APH-0911, a nanotechnology-based prodrug for cancer treatment. Additionally, Aphios is engaged in developing technologies related to supercritical fluids for the production of natural pharmaceuticals, as well as specialized equipment for various applications, including microbial cell disruption and biomass pretreatment for biofuels. The company also provides virology testing services to validate viral clearance and inactivation.

Health 360x brings together patients, clinicians, and researchers to enhance the health of neglected groups. Health 360x is changing clinical research through point-of-care access for patients and providers in non-academic practices that mostly serve African Americans and other patients who have historically been underrepresented in corporate and NIH clinical trials.

Washington University School of Medicine is the medical school of Washington University in St. Louis.A leader in medical research, teaching and patient care, Washington University School of Medicine is currently ranked fourth in the nation by U.S. News & World Report. The School’s 2,100 employed and volunteer faculty physicians and clinicians -- known as Washington University Physicians -- are also medical staff members of Barnes-Jewish and St. Louis Children’s hospitals. The clinical practice group provides care to more than 430,000 children and adults at 49 clinical sites annually. Together, the institutions located on the Washington University Medical Center campus employ more than 21,000 clinicians, scientists, residents, fellows, administrators and support staff.

Scene Health, formerly known as Emocha Health, addresses the longstanding issue of medication nonadherence by utilizing a comprehensive approach that combines technology, education, and personalized support. The company offers a mobile app that facilitates daily video check-ins, allowing patients to connect with healthcare professionals, including pharmacists and nurses, from anywhere at any time. This innovative platform enhances the traditional Directly Observed Therapy model by providing personalized video coaching and motivational content, thereby engaging patients and their families in their health management. Scene Health's solutions are designed to tackle the $500 billion medication nonadherence problem by identifying and addressing barriers related to social determinants of health. With over 120 clients in the healthcare sector, Scene Health aims to improve medication adherence for patients with chronic and infectious diseases, ultimately enhancing public health outcomes and reducing healthcare costs associated with nonadherence.

Feinstein Institute For Medical Research is the research arm of Northwell Health, the largest health care provider and private employer in New York State. Home to 50 research labs, 3,000 clinical research studies and 5,000 researchers and staff, the Feinstein Institutes raises the standard of medical innovation through its five institutes of behavioral science, bioelectronic medicine, cancer, health innovations and outcomes, and molecular medicine. We make breakthroughs in genetics, oncology, brain research, mental health, autoimmunity, and are the global scientific leader in bioelectronic medicine – a new field of science that has the potential to revolutionize medicine.

TransCode Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Boston, Massachusetts, focused on the discovery and development of microRNA (miRNA) therapeutics to treat metastatic diseases. Founded in 2016, the company is dedicated to combating cancer through the targeted eradication of metastatic tumor cells, primarily leveraging its proprietary TTX nanoparticle platform. Its lead therapeutic candidate, TTX-MC138, aims to inhibit microRNA-10b, a key biomarker associated with metastasis, and has shown promising preclinical validation. Additionally, TransCode is advancing a portfolio of innovative RNA therapeutic candidates designed to address the challenges of RNA delivery, thereby expanding therapeutic options for various genetic targets within oncology.

Vivani Medical is a preclinical-stage biopharmaceutical company focused on developing innovative medical solutions for chronic diseases and visual impairments. The company specializes in creating implantable visual prosthetics, including a retinal prosthesis designed to restore sight to individuals blinded by outer retinal degenerations such as Retinitis Pigmentosa. Utilizing its proprietary NanoPortal technology, Vivani Medical manufactures miniaturized, subdermal implants that facilitate long-term, consistent delivery of various medications. Through its commitment to research and development, Vivani Medical aims to enhance the quality of life for patients, enabling greater independence for those affected by vision loss and chronic conditions. Founded in 1998 and based in Sylmar, California, the company operates with two main divisions: Biopharm and Neuromodulation, focusing on innovative solutions in the medical field.

AivoCode Inc. is a biotechnology company specializing in the treatment and management of critical neurological diseases, including brain injury and Alzheimer's disease. The company has developed proprietary peptides that can specifically identify molecular changes associated with these conditions. These peptides enhance the delivery of various therapeutics and diagnostic agents directly to affected areas of the brain, improving both therapeutic efficacy and non-invasive detection methods. AivoCode's technology aims to facilitate site-specific drug delivery, thereby enabling better recognition and treatment of Alzheimer's disease and other neurodegenerative disorders. The development of AivoCode's technology has been supported entirely through non-dilutive federal grant funding.

OncoSpherix, Inc., based in Atlanta, Ga, is a pre-clinical stage oncology drug development company that is advancing a proprietary platform of first-in-class small molecule therapeutics that are designed to improve the quality of life and survival for people with many forms of cancer by targeting a common feature of solid tumors: the activation of hypoxia inducible factor-1 (HIF-1). Nearly all solid cancers grow faster than their blood supply, leading to regions of low oxygen in the tumors and HIF activation. The HIFs in turn induce the expression of over 100 genes that help tumor cells survive and spread. OncoSpherix has several classes of small molecules that block activation of HIF-1 through novel mechanisms. OncoSpherix’s lead clinical candiate has been shown in mouse models to reduce primary tumor growth, inhibit metastases, and prolong survival in many types of cancer (glioblastoma, pancreatic cancer, uveal melanoma, lung cancer, breast cancer). Importantly, the agents are well tolerated and can be combined with therapeutics that work in well oxygenated regions of cancers, leading to dramatically enhanced cancer control.

Montefiore Health System offers advanced specialty programs, cardiology, and cardiac surgery. They provide cancer care, children’s health, tissue, and organ transplantation. Their services include women’s health, surgery, and surgical subspecialties. If anyone wants to contact them please contact them via phone call or email.

Arkansas Children's Research Institute is a not-for-profit organization affiliated with Arkansas Children's, Inc., and is dedicated to advancing pediatric health through research. It operates in conjunction with Arkansas Children's Hospital, the only pediatric medical center in Arkansas and one of the largest in the nation, which spans 29 city blocks and features 370 beds. The hospital employs around 500 physicians and more than 4,400 staff members, focusing on innovative medical research, surgical procedures, and intensive treatments aimed at improving children's health and development. The institute's research efforts contribute to the hospital's reputation for medical breakthroughs and have garnered recognition, including being ranked on the FORTUNE 100 Best Companies to Work For list for three consecutive years.

The Oklahoma Medical Research Foundation (OMRF) is a non-profit biomedical research institute dedicated to understanding and treating various devastating illnesses, including Alzheimer's, heart disease, lupus, multiple sclerosis, and cancer. It operates a research facility, providing services and access to resources that facilitate drug discoveries and improve patient care.

Chemeleon has developed an innovative diagnostic platform that provides rapid, accurate, and affordable detection of a wide array of analytes, including drugs, proteins, and viruses. This proprietary in vitro diagnostic technology delivers a colorimetric readout within minutes, visible to the naked eye, without requiring reagents, instruments, or specialized training. This capability facilitates decentralized testing, allowing clinicians to extend point-of-care diagnostics and enabling individuals to self-administer tests at the point of need. By combining selective molecular receptors with colorimetric nanomaterial reporters, Chemeleon's diagnostics offer immediate and actionable results, significantly improving patient outcomes while reducing costs. Notably, under a National Institutes of Health grant, the company created a test to detect beta-2-transferrin, aiding healthcare providers in promptly diagnosing cerebrospinal fluid leaks, which can drastically lower morbidity and patient stay duration. This technology meets the World Health Organization's ASSURED criteria, making it suitable for both advanced healthcare settings and resource-limited environments, thereby revolutionizing the accessibility of critical diagnostic services.

Actuated Medical, Inc. engages in outsourced research and development, designing and modeling, prototyping, and manufacturing medical devices. It offers occlusion clearing systems, such as NG-Clear for removing and disintegrating nasogastric (NG) tube clogs; and PEG-Clear for clearing and breaking up percutaneous endoscopic gastrostomy (PEG) tube clogs. The company also provides controlled tissue penetration systems, including resonance assisted insertion lancets for humane blood sampling of research subjects; low insertion force epidural systems for the entry of epidural needles; and resonance assisted vascular entry needles for aiding in vascular access for compromised and difficult access patients. In addition, Actuated Medical, Inc. offers magnetic resonance imaging compatible systems, such as direct drive motor for improving patient care by enabling various diagnostic and surgical procedures to be performed during MRI imaging; and transdermal patches for administering long-term and controlled-delivery medications subcutaneously. The company was formerly known as Piezo Resonance Innovations, Inc. and changed its name to Actuated Medical, Inc. in September 2011. Actuated Medical, Inc. was founded in 2006 and is based in Bellefonte, Pennsylvania.

Case Western Reserve University (CWRU) is a private research university located in Cleveland's University Circle. Established in 1843, it comprises various schools including Medicine, Law, Engineering, Arts and Sciences, Nursing, Social Sciences, Dental Medicine, Management, and Mandel School of Applied Social Sciences. CWRU is renowned for its biomedical discoveries, medical education, and top-ranked programs such as international law, health law, and intellectual property law. It offers practical experiences like real-client work and full-time practice experiences to students across various disciplines. The university is accredited by several professional associations and holds membership in the Association of American Universities.

Linshom is focused on providing continuous respiratory monitoring solutions that include measurements of Tidal Volume at the patient's bedside or in home settings. The company has developed a wearable sensor that is FDA cleared, designed to enable continuous, predictive respiratory monitoring. This technology allows for early detection of respiratory decline, which can help prevent costly rapid response situations, ICU transfers, and potential fatalities. By addressing a critical unmet medical need, Linshom aims to enhance patient care and improve outcomes through advanced respiratory monitoring capabilities.

Aptinyx Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and developing innovative therapies for brain and nervous system disorders. Founded in 2015 and based in Evanston, Illinois, the company focuses on novel, synthetic small molecules that modulate the NMDA receptor, enhancing communication pathways between nerve cells. Its primary products in development include NYX-2925, which is undergoing Phase II trials for painful diabetic peripheral neuropathy and fibromyalgia, and NYX-783, currently in Phase I trials for post-traumatic stress disorder. Additionally, Aptinyx is developing NYX-458, another NMDA receptor modulator, which is in Phase I clinical studies aimed at treating cognitive impairment associated with Parkinson’s disease. The company also collaborates with Allergan to develop compounds for major depressive disorder, underscoring its commitment to addressing significant unmet medical needs in the central nervous system arena.

Feinstein Institute For Medical Research is the research arm of Northwell Health, the largest health care provider and private employer in New York State. Home to 50 research labs, 3,000 clinical research studies and 5,000 researchers and staff, the Feinstein Institutes raises the standard of medical innovation through its five institutes of behavioral science, bioelectronic medicine, cancer, health innovations and outcomes, and molecular medicine. We make breakthroughs in genetics, oncology, brain research, mental health, autoimmunity, and are the global scientific leader in bioelectronic medicine – a new field of science that has the potential to revolutionize medicine.

University of Arkansas for Medical Sciences is an academic health center focusing on medical education, research, and clinical programs. It offers various medical services, including specialized care in areas such as women's health, cancer treatment, orthopedics, stroke care, and trauma.

Neurovations, a patient care and innovation company, was founded in 1992 by CEO Dr. Eric Grigsby. Today, Neurovations is a national leader in medical device and pharmaceutical innovation, clinical research, and a world-class education program focusing in pain and neuroscience. Dr. Grigsby is deeply connected to the healthcare community through our non-profit HealthRoots Foundation. Our unwavering mission is to inspire hope and to contribute to the health and well-being of our patients and communities through integrated clinical practice, research, and education.

The Georgia Clinical & Translational Science Alliance (Georgia CTSA) is an inter-institutional magnet that concentrates basic, translational, and clinical research investigators, community clinicians, professional societies, and industry collaborators in dynamic clinical and translational research projects. Emory engaged three of its close academic partners - Morehouse School of Medicine (MSM), Georgia Institute of Technology (Georgia Tech), and the University of Georgia (UGA) - to form the Georgia CTSA. This partnership, a strategic multi-institutional alliance, offers compelling, unique, and synergistic advantages to research and patients statewide. Emory is a national leader in healthcare and biomedical research as well as an outstanding leader in clinical and translational research training and education. Morehouse School of Medicine is a nationally recognized historically black institution that brings ethnic diversity to biomedical research, addresses health disparities through successful community engagement research, and serves as a pipeline for training minority researchers. Georgia Tech is a national leader in biomedical engineering and the application of innovative systems engineering to healthcare solutions. UGA has a proven track record in outstanding basic and translational research and, as the State’s land-grant institution, offers a robust statewide network that enhances community outreach, service, and research. These institutions extend their current partnerships in healthcare, education, and cutting-edge interdisciplinary research to synergize Georgia CTSA. Created in 2017 as one of a national consortium striving to improve the way biomedical research is conducted across the country. The consortium, funded through the National Center for Advancing Translational Sciences, part of the National Institutes of Health's Clinical and Translational Science Awards (CTSA), shares a common vision to translate laboratory discoveries into treatments for patients, engage communities in clinical research efforts and train the next generation of clinical investigators.

The Indiana University School of Medicine is the largest medical school in the United States. The IU School of Medicine, which is made up of five fundamental science departments and twenty clinical departments, provides superior training for students interested in pursuing a medical degree. The school launched a new medical education curriculum with the Class of 2020 that better represents the modern U.S. health care environment and delivery methods, preparing students to practice medicine in a team-based, multidisciplinary setting.

Allen Institute for Brain Science is a non-profit medical research organization dedicated to understanding the complexities of bioscience. The organization encompasses three entities, the Allen Institute for Brain Science, Allen Institute for Cell Science, and Paul G. Allen Frontiers Group. Its mission is to accelerate the understanding of how the brain works in health and disease. It creates useful public resources, drive technological and analytical advances, and discover fundamental brain properties through integration of experiments using a big science, team science, and open science approach. Allen Institute for Brain Science was founded on 2003 and is based in Seattle, Washington.

Wake Forest School of Medicine, located in Winston-Salem, North Carolina, is an esteemed educational institution founded in 1902, focusing on biomedical research and primary care education. The school offers students hands-on experience with patients from the first week of medical school, emphasizing practical training alongside academic learning. With a nationally recognized research program, Wake Forest School of Medicine has secured over $400 million in extramural funding, supporting its mission to advance medical knowledge and care. The institution educates nearly 1,900 students and fellows, including physicians, basic scientists, and allied clinical professionals, preparing them for a range of careers in the medical field.

Arkana Laboratories offers renal pathology, neuropathology and testing, apol1, and biopharmaceutical services. It is a provider of esoteric pathologic services and a centre for pathology focused on improving care for patients. For inquiries, email, telephone numbers, and physical addresses are available on their website.

Evaxion Biotech A/S is a clinical-stage biotechnology company focused on utilizing artificial intelligence to decode the human immune system and develop innovative immunotherapies for cancer and infectious diseases. The company leverages its proprietary AI-immunology technology to create a diverse pipeline of product candidates, which includes three patient-specific cancer immunotherapies—two of which are in Phase I/IIa clinical trials. In addition to its cancer treatments, Evaxion is also advancing a portfolio of vaccines aimed at preventing bacterial and viral infections, with one program targeting Methicillin-resistant Staphylococcus aureus currently in preclinical development. By combining AI with immunology, Evaxion seeks to improve therapeutic efficacy for patients with unmet medical needs.

Glyphic Biotechnologies is a biotechnology company focused on developing an advanced protein sequencing platform that aims to enhance understanding of biological functions and diseases. Unlike DNA sequencing, which offers limited insights, this next-generation platform provides deeper knowledge through single-molecule, massively parallel sequencing. By improving binding affinity and consistency, Glyphic's technology supports the creation of personalized and precision cancer vaccines tailored to individual patients. The company's innovative approach enables scientists and researchers to develop novel therapeutics and diagnostics, ultimately advancing the comprehension of human biology and disease mechanisms.

Oligomerix, Inc. is a biopharmaceutical company based in Bronx, New York, founded in 2006. It specializes in developing therapeutics for Alzheimer’s disease and related neurodegenerative disorders through innovative research on tau proteins. The company focuses on small molecule drug discovery, specifically targeting tau oligomers and developing tau protease inhibitors. In addition to small molecules, Oligomerix is involved in creating antibody fragments that serve as biomarkers to aid in drug development, diagnostics, and therapeutic applications. By leveraging its novel approaches to generate stable amyloid oligomers, Oligomerix aims to enhance target identification and validation, contributing to improved treatment options for various tauopathies, including progressive supranuclear palsy and frontotemporal dementia.

Arkansas Children's Research Institute is a not-for-profit organization affiliated with Arkansas Children's, Inc., and is dedicated to advancing pediatric health through research. It operates in conjunction with Arkansas Children's Hospital, the only pediatric medical center in Arkansas and one of the largest in the nation, which spans 29 city blocks and features 370 beds. The hospital employs around 500 physicians and more than 4,400 staff members, focusing on innovative medical research, surgical procedures, and intensive treatments aimed at improving children's health and development. The institute's research efforts contribute to the hospital's reputation for medical breakthroughs and have garnered recognition, including being ranked on the FORTUNE 100 Best Companies to Work For list for three consecutive years.

Vivani Medical is a preclinical-stage biopharmaceutical company focused on developing innovative medical solutions for chronic diseases and visual impairments. The company specializes in creating implantable visual prosthetics, including a retinal prosthesis designed to restore sight to individuals blinded by outer retinal degenerations such as Retinitis Pigmentosa. Utilizing its proprietary NanoPortal technology, Vivani Medical manufactures miniaturized, subdermal implants that facilitate long-term, consistent delivery of various medications. Through its commitment to research and development, Vivani Medical aims to enhance the quality of life for patients, enabling greater independence for those affected by vision loss and chronic conditions. Founded in 1998 and based in Sylmar, California, the company operates with two main divisions: Biopharm and Neuromodulation, focusing on innovative solutions in the medical field.

Feinstein Institute For Medical Research is the research arm of Northwell Health, the largest health care provider and private employer in New York State. Home to 50 research labs, 3,000 clinical research studies and 5,000 researchers and staff, the Feinstein Institutes raises the standard of medical innovation through its five institutes of behavioral science, bioelectronic medicine, cancer, health innovations and outcomes, and molecular medicine. We make breakthroughs in genetics, oncology, brain research, mental health, autoimmunity, and are the global scientific leader in bioelectronic medicine – a new field of science that has the potential to revolutionize medicine.

Case Western Reserve University (CWRU) is a private research university located in Cleveland's University Circle. Established in 1843, it comprises various schools including Medicine, Law, Engineering, Arts and Sciences, Nursing, Social Sciences, Dental Medicine, Management, and Mandel School of Applied Social Sciences. CWRU is renowned for its biomedical discoveries, medical education, and top-ranked programs such as international law, health law, and intellectual property law. It offers practical experiences like real-client work and full-time practice experiences to students across various disciplines. The university is accredited by several professional associations and holds membership in the Association of American Universities.

Aural Analytics, Inc. is a Scottsdale, Arizona-based company founded in 2015 that focuses on developing applications for monitoring brain health. The company has created a multi-modal brain health analytics platform that utilizes advances in artificial intelligence, neuroscience, and speech analytics to detect changes in neurological health. By leveraging proprietary metrics, Aural Analytics transforms smartphones and tablets into effective brain health monitors, capturing subtle, clinically relevant aspects of a patient's condition through speech samples. This technology enhances traditional functional rating scales used in clinical trials by providing objective, continuous outcomes, thereby allowing for more reliable evaluations of drug efficacy and other interventions. Aural Analytics' platform aims to reveal incremental changes in neurological health, facilitating accurate assessments by medical professionals.

The Oklahoma Medical Research Foundation (OMRF) is a non-profit biomedical research institute dedicated to understanding and treating various devastating illnesses, including Alzheimer's, heart disease, lupus, multiple sclerosis, and cancer. It operates a research facility, providing services and access to resources that facilitate drug discoveries and improve patient care.

Eliaz Therapeutics has developed a patented medical device that selectively removes galectin-3 from human blood, addressing currently untreatable life-threatening diseases. This device targets galectin-3, a protein associated with conditions such as diabetes, chronic kidney disease, organ fibrosis, and cancer. By employing a single-use apheresis column that utilizes a proprietary capturing molecule, the device effectively eliminates both bound and free galectin-3 from circulation. This innovative approach offers a less invasive treatment option with fewer side effects compared to traditional therapies, enabling physicians to provide effective care for patients suffering from acute kidney injury, sepsis, and other inflammatory and fibrotic diseases. The device is designed for easy integration into existing hospital practices, enhancing its potential for widespread adoption.

AVM Biotechnology LLC is a clinical-stage regenerative medicine company based in Seattle, Washington. Founded in 2008, it specializes in the discovery, development, and commercialization of stem cell technologies for applications in regenerative medicine, oncology, and human biologics. The company offers a range of innovative compounds aimed at enhancing organ regeneration and immune system recovery through the modulation of stem cell binding. Its platforms include Boutique Biologics, which focuses on personalized medicine by creating patient-specific biologics that minimize immunogenicity, and Better Biologics, which enables large-scale production of human biologics that address resistance issues. AVM's lead drug, AVM0703, is an advanced formulation of dexamethasone designed to activate the body’s immune cells against cancer, autoimmunity, and infectious diseases. The company is supported by a Scientific Advisory Board comprised of experts in cancer and immunology, and it is engaged in various preclinical development projects, including small molecules and antibody-based candidates.

NovoMedix is a biotechnology company focused on developing novel orally available small molecules aimed at treating fibrotic disorders and certain cancers, particularly triple negative breast cancer (TNBC). The company’s innovative compounds demonstrate significant efficacy in animal models for fibrosis and possess unique properties that offer cardioprotective effects in conjunction with standard chemotherapy treatments. This is especially relevant for TNBC patients who often experience delayed cardiomyopathy as a result of anthracycline treatments, which can lead to cardiovascular disease being a leading cause of death among breast cancer survivors. By co-targeting pathways involved in both cancer treatment and heart protection, NovoMedix aims to enhance patient responses to therapy while significantly reducing the risk of cardiotoxicity. The company is preparing to initiate IND enabling studies for its lead candidate, with the goal of delivering this promising therapy to TNBC patients as quickly as possible.

University of Arkansas for Medical Sciences is an academic health center focusing on medical education, research, and clinical programs. It offers various medical services, including specialized care in areas such as women's health, cancer treatment, orthopedics, stroke care, and trauma.

Benaroya Research Institute at Virginia Mason (BRI) is one of the few research institutes in the world dedicated to discovering causes and cures to eliminate autoimmune and immune system diseases. At BRI, their scientists aren’t focused on eliminating one or two autoimmune diseases—they’re taking on all 80. Because autoimmune diseases are connected, so is the way they’re fighting them. They're applying the breakthroughs they make against individual autoimmune diseases to make progress against them all. Through collaboration and cooperation between researchers, across clinical trials and with other institutions, they connect laboratory research to clinical trials and translate discoveries to real-life applications. As a world leader in scientific innovation, they’re leveraging this progress to eliminate autoimmune and immune system diseases in the future. Their discoveries are also having significant impact on people living with autoimmune and immune system diseases today—by improving the ability to predict disease risk, facilitate treatment, decrease progression of these diseases and make related therapies safer and more effective.

Dascena, Inc. is a healthcare technology company based in Oakland, California, that specializes in developing machine learning algorithms aimed at enhancing patient care and early disease intervention. Founded in 2018, Dascena focuses on creating algorithmic software that processes electronic health record data to predict critical conditions such as acute decompensation, sepsis, and acute kidney injury. By leveraging extensive clinical research, the company provides tools that support clinical decision-making, facilitate point-of-care diagnostics, and serve as biopharma companion diagnostics. Dascena's innovations address significant unmet healthcare needs, ultimately aiming to improve care outcomes and save lives through timely and accurate interventions.

NYU Langone Health is a nonprofit academic medical center located in New York City, recognized for its commitment to patient-centered care, research, and medical education. The organization offers a comprehensive range of healthcare services, diagnosing and treating various conditions, including lung diseases, joint and muscle disorders, neurological disorders, blood disorders, and gastrointestinal issues. As a center of excellence, NYU Langone Health integrates advanced medical practices with innovative research to enhance patient outcomes and contribute to advancements in healthcare.

Weill Cornell Medicine operates as a leading medical and graduate school in New York City, focusing on excellence in patient care, scientific discovery, and the education of future physicians. The institution provides a comprehensive range of services, including medical consultancy, healthcare programs, and educational guidance, aimed at healthcare service providers, medical students, and governmental organizations. In addition to its educational mission, Weill Cornell Medicine includes specialized centers such as the Weill Cornell Vein Treatment Center, which offers treatments for various venous conditions and related health issues. The Information Technologies & Services Department plays a crucial role in supporting the institution’s objectives by delivering extensive IT infrastructure and services, enhancing research and clinical operations through innovative technology solutions. This multidisciplinary approach positions Weill Cornell Medicine as a leader in both medicine and technology.

Meridian Bioscience is an integrated life science company that develops, manufactures, and distributes clinical diagnostic test kits for gastrointestinal, viral, respiratory, and parasitic infectious diseases. The company specializes in molecular and immunological reagents, providing tools that support the discovery and diagnosis of various medical conditions. In addition to diagnostic test kits, Meridian offers bulk antigens, antibodies, PCR and qPCR reagents, nucleotides, and bioresearch reagents, serving researchers and other diagnostic manufacturers. Moreover, the company engages in contract development and manufacturing of proteins and other biologicals under cGMP conditions, catering to biopharmaceutical and biotechnology firms involved in drug and vaccine research. Meridian operates through three segments: U.S. Diagnostics, European Diagnostics, and Life Science, emphasizing its commitment to enhancing healthcare outcomes through innovative solutions.

Novoron Bioscience, Inc. is a biotechnology company based in San Diego, California, focused on developing innovative treatments for various central nervous system (CNS) disorders, including multiple sclerosis, spinal cord injury, glaucoma, and stroke. Founded in 2013, the company specializes in creating therapeutic approaches that target neurological damage and diseases using novel science centered on lipoprotein receptors. Novoron is advancing a pipeline of pre-clinical therapies aimed at addressing conditions such as Alzheimer's disease, tauopathies, and demyelinating diseases, with the goal of offering effective treatments for conditions that currently lack viable options. The company's research emphasizes repairing damage to the brain and spinal cord, ultimately striving to enhance recovery for patients suffering from debilitating neurological conditions.

Subtle Medical, Inc. is a healthcare technology company based in Menlo Park, California, that specializes in developing AI-powered medical imaging software for clinical imaging centers and hospitals. Founded in 2017, the company offers products such as SubtleMR and SubtlePET, both of which are FDA cleared and CE marked. These technologies enhance image quality in magnetic resonance imaging (MRI) and positron emission tomography (PET) exams by reducing noise and increasing sharpness, ultimately improving workflow efficiency while ensuring patient safety. Subtle Medical also features SubtleGAD, a technology recognized by the Radiological Society of North America, which aims to make imaging exams safer. The company employs a vendor-agnostic AI infrastructure that integrates seamlessly with existing scanners, allowing imaging providers to serve more patients effectively by enhancing image acquisition without disrupting their current workflow. Through its innovations, Subtle Medical seeks to improve the quality, value, and accessibility of medical imaging while significantly lowering costs and radiation exposure.

Arkansas Children's Research Institute is a not-for-profit organization affiliated with Arkansas Children's, Inc., and is dedicated to advancing pediatric health through research. It operates in conjunction with Arkansas Children's Hospital, the only pediatric medical center in Arkansas and one of the largest in the nation, which spans 29 city blocks and features 370 beds. The hospital employs around 500 physicians and more than 4,400 staff members, focusing on innovative medical research, surgical procedures, and intensive treatments aimed at improving children's health and development. The institute's research efforts contribute to the hospital's reputation for medical breakthroughs and have garnered recognition, including being ranked on the FORTUNE 100 Best Companies to Work For list for three consecutive years.